Skip to main content

Volume 9 Supplement 5

Recombinant activated factor VIIa and hemostasis in critical care: a focus on trauma

Reviews

Edited by John B Holcomb

Supported by an educational grant from Novo Nordisk

Recombinant activated factor VIIa and hemostasis in critical care: a focus on trauma.

  1. Blood transfusion has been used to treat the injured since the US Civil War. Now, it saves the lives of tens of thousands of injured patients each year. However, not everyone who receives blood benefits, and s...

    Authors: John R Hess and Seppo Hiippala
    Citation: Critical Care 2005 9(Suppl 5):S10
  2. Preclinical studies in animals and ex vivo human blood have provided a solid rationale for conducting prospective randomized trials in trauma patients. Small animal models have been utilized to study the efficacy...

    Authors: Martin A Schreiber, John B Holcomb and Rasmus Rojkjaer
    Citation: Critical Care 2005 9(Suppl 5):S25
  3. The hemostatic properties of recombinant activated factor VII (rFVIIa) are established in patients with inherited or acquired hemophilia with inhibitors and in patients with congenital factor VII deficiencies....

    Authors: R Michael Grounds and Charles Bolan
    Citation: Critical Care 2005 9(Suppl 5):S29

    The Erratum to this article has been published in Critical Care 2005 9:560

  4. In this article we describe the current use of recombinant activated factor VII (rFVIIa; NovoSeven®) in trauma patients. Emphasis is placed on current uses as defined by key studies, efficacy data, and safety dat...

    Authors: Alicia M Mohr, John B Holcomb, Richard P Dutton and Jacques Duranteau
    Citation: Critical Care 2005 9(Suppl 5):S37